Hirotomo Machiyama
Suita, 5650871, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: May 08, 2026
Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.
Journal: Thoracic cancer
Published: January 31, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy.
Journal: Respiratory medicine
Published: December 24, 2025
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: August 12, 2025
Lenvatinib Combined with PD-1 Blockade Therapy Benefits Gastric Cancers through Immunosuppressive Macrophage Modulation.
Journal: Cancer immunology research
Published: August 07, 2025
A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC.
Journal: JTO clinical and research reports
Published: May 17, 2025
Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome.
Journal: Journal of medical cases
Published: December 24, 2022
Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: June 06, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026